Medisun launched the “Hong Kong Regenerative Medisun Association”
On May 28, 2018, the Hong Kong Regenerative Medisun Association, which was initiated by representatives from the Hong Kong Regenerative Medisun Industry and academic circles, was formally established under the auspices of the Medisun Medical Group.
Hong Kong Regenerative Medisun Association goals
The Hong Kong Regenerative Medisun Association was founded by experts, scholars, industry representatives and people of insight in the field of regenerative Medisun in Hong Kong and around the world. The purpose of the association is to establish a consensus platform for the regenerative Medisun industry in Hong Kong, promote the development of the regenerative Medisun industry, encourage and promote international cooperation, and propose to the Hong Kong SAR government the recommendations of the regenerative Medisun industry on industry regulations and actively influence industry rules. The establishment and improvement of the company provides effective technical and management advice to the Hong Kong government, Hong Kong public health agencies and companies in the industry.
The first meeting of the Hong Kong Regenerative Medisun Association (May 28, 2018)
On the afternoon of May 28, representatives from Hong Kong’s medical health, regenerative Medisun and biotechnology fields, doctors, pharmacists, chemists and university researchers gathered to discuss and elect the first council of the Hong Kong Regenerative Medisun Association.They read the charter of the association and clarify the duties of the board. At the same time, they have had a heated discussion on the regulatory documents issued by the Hong Kong SAR Government on Advanced Therapy Products. They agreed to regulate the direction of document guidance and proposed a number of issues that need to be clarified, including:
1. Professional qualifications required by the licensee of the Regenerative Medisun and Stem Cell Research and Development Organization;
2. Advanced Therapy Products is regulated by the Pharmacy and Poisons Ordinance (Cap. 138). However, since the production process and user definition of cellular products and pharmaceutical products are different, they should be clarified accordingly;
3. With reference to the requirements of the international GMP/PICS standard, which standard should be achieved in the cell laboratory qualification of existing regenerative Medisun institutions;
4. After the specific regulation is in force, whether there should be a transition period, so that the industry has time to adjust and cooperate;
5. Submit the Advanced Therapy Products comments and submit them to the Hong Kong Department of Health.
Member of the First Council of the Hong Kong Regenerative Medisun Association
|
Position
|
Name
|
Qualifications
|
|
Chairman
|
Danny Wong Mr. Wang Xiaofeng
|
Founder and Chairman of Medisun Medical Group, years of investment experience in the field of regenerative Medisun, understanding the development and trends of the biotechnology industry
|
|
Vice President
|
Joseph Wang Dr. Wang Qiyuan
|
Registered as a doctor, founder of the Hong Kong Stem Cell Center, enriching the clinical experience of regenerative Medisun
|
|
Vice President
|
David Leung Mr. Liang Yaoming
|
Registered pharmacist, familiar with pharmaceutical regulations and GMP requirements
|
|
Vice Chairman
|
Gregory Cheng Professor Zheng Yanming
|
Hematology expert, Professor of the University of Macau Health Sciences
|
|
Director | Treasurer
|
Kenneth Lee Dr. Li Zhisheng
|
Registered as a doctor, B Q Anti-aging Center Consultant
|
|
Director
|
Philip Choy Dr. Cai Shaolong
|
Ph.D. in Natural Medisun, Madison Biomedical Director
|
|
Director
|
Daniel Tam Dr. Tan Yizhu
|
Registered as a medical laboratory technologist, director of the Trans-Olympic Blood Bank Laboratory, focusing on cell culture technology for many years
|
|
Director
|
Vivien Leung Ms. Liang Yiqun
|
Registered as a medical laboratory technologist, manager of the Trans-Olympic Blood Bank Laboratory, familiar with quality management
|
|
Director
|
Chris Wong Dr. Huang Libao
|
Registered as a medical laboratory technologist, director of HKMDPC, molecular biodiagnostic expert
|
|
Secretary
|
Sidney Tam Dr. Tan Guozhen
|
Chief Executive Officer, Life Clinic, Health Management Consultant
|
|
Secretary
|
Allen Chan Mr. Chen Yuxin
|
Registered as a medical laboratory technologist, familiar with quality management
|
The first meeting of the Hong Kong Regenerative Medisun Association (May 28, 2018)
Hong Kong Regenerative Medisun Association’s recent work plan
Next, the Hong Kong Regenerative Medisun Association will issue letters to the organizations including the Hong Kong Department of Health, the Hong Kong Stock Exchange, the Hong Kong University Biomedical Science, Life Sciences, and the Global Regenerative Medisun Alliance (ARM). include:
1. Announced the official establishment of the Hong Kong Regenerative Medisun Association
2. Announce the initial membership list of the Hong Kong Regenerative Medisun Council, association charter, association vision and goals
3. Call for the support and participation of experts, scholars and industry representatives from Hong Kong and around the world
4. Propose to the Hong Kong Government to clarify regulatory regulations on Advanced Medisun and Advanced Therapy Products
Special thanks
Thank you for taking the time to attend the representatives of the institutions, including:
|
Medisun Medical Group | Medisun Reproductive Medisun Center
|
|
Hong Kong Life Science and Technology Group Co., Ltd.
|
|
Standard Pathology Laboratory Co., Ltd.
|
|
BIH
|
|
Living Tissues company limited
|
|
BIB Health Care Centre
|
|
Hongxin Medical Center
|
|
Austa beauty
|
|
Hong Kong International Regenerative Medisun Centre
|
|
HKMPDC
|
|
Huixin Technology
|
|
Guangzhou Biological Institute
|
|
Trans-along cord blood bank
|
|
Hong Kong Stem Cell Center
|
|
Life Length
|
|
Biocell
|
|
Cordlife
|
For more information, please visit http://www.medisun.hk/
